Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE1, PHASE2
Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.
Condition: Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07, phaseI/II
NCT07432022
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: strict_eligibility_signal | complex_intervention_signal
Stopped reason
Context when available
No stop reason available in the current public record.